In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness [PDF]
PLoS Neglected Tropical Diseases, 2012 Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and ...
Caecilia Schmid +2 more
exaly +44 more sources
PLoS Neglected Tropical Diseases, 2021 Nifurtimox is a recommended treatment for Chagas disease, but data from treated children are limited. We investigated the efficacy, safety and tolerability of nifurtimox administered as divisible, dispersible 30 mg and 120 mg tablets in children with ...
, Luis Castro, Ulrike Grossmann
exaly +2 more sources
Development of an ionic liquid-based dispersive liquid–liquid microextraction method for the determination of nifurtimox and benznidazole in human plasma [PDF]
Talanta, 2013 Dispersive ionic liquid–liquid microextraction combined with liquid chromatography and UV detection was used for the determination of two antichagasic drugs in human plasma: nifurtimox and benznidazole.
Altcheh, Jaime Marcelo +5 more
exaly +4 more sources
Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease [PDF]
Tropical Medicine and Infectious DiseaseChagas disease, caused by Trypanosoma cruzi, remains a neglected tropical disease with limited and often suboptimal chemotherapeutic treatment options.
Ana Lia Mazzeti +4 more
doaj +2 more sources
Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion. [PDF]
PLoS Neglected Tropical DiseasesAnti-trypanosomal therapy is generally recommended for individuals under age 50 with the indeterminate form of Chagas disease to prevent disease progression. However, benznidazole and nifurtimox are associated with adverse drug reactions.
Katherine Reifler +13 more
doaj +2 more sources
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
Pharmaceutics, 2022 Chagas disease (CD) is a parasitic zoonosis endemic in Central and South America affecting nearly 10 million people, with 100 million people at high risk of contracting the disease.
Dolores R Serrano, Katerina Lalatsa
exaly +3 more sources
3D-Printed Tablets of Nifurtimox: In Vitro and In Vivo Anti-Trypanosoma cruzi Studies [PDF]
PharmaceuticsBackground/Objectives: Chagas disease is a neglected tropical disease caused by infection with the parasite Trypanosoma cruzi. Benznidazole and nifurtimox are the only approved drugs for treating this condition, but their low aqueous solubility may lead ...
Giselle R. Bedogni +6 more
doaj +2 more sources
Redefining the treatment of Chagas disease: a review of recent clinical and pharmacological data for a novel formulation of nifurtimox. [PDF]
PLoS Neglected Tropical DiseasesNifurtimox has been used for over 50 years to treat patients with Chagas disease, a potentially life-threatening neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi.
Jaime Altcheh +4 more
doaj +2 more sources
Concomitant diagnosis of Trypanosoma cruzi and HIV in a patient with neurologic manifestations: A case report [PDF]
Brazilian Journal of Infectious DiseasesAmerican trypanosomiasis or Chagas disease is a vector-borne infection caused by the protozoan parasite Trypanosoma cruzi, characterized by acute and chronic phases; reactivations due to immunosuppression can occur.
Emmanuel Molina Solano +4 more
doaj +2 more sources
PLoS Neglected Tropical Diseases, 2012 A non-targeted metabolomics-based approach is presented that enables the study of pathways in response to drug action with the aim of defining the mode of action of trypanocides.
Isabel M Vincent +2 more
exaly +3 more sources